News

Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Weight-loss company Noom pivots to smaller doses of compounded Wegovy
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.
Novo Nordisk and US biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat
Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...
STAT56m
Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...
Zacks Investment Research on MSN23h
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...
Compounded versions of weight loss shots in short supply
Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...
Health on MSN19h
This New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?
Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...